Terns Pharmaceuticals, INC Form 4 insider transactions

Terns Pharmaceuticals, Inc. Director Hongbo Lu was granted 45,000 stock options with an exercise price of $4.10, vesting on the earlier of the first anniversary of the grant date or the next Annual Meeting.

Jeffrey B Kindler, a Director at Terns Pharmaceuticals, Inc., was granted 45,000 stock options with an exercise price of $4.10, aligning his interests with long-term shareholder value.

Terns Pharmaceuticals, Inc. Director Heather D. Turner was granted 45,000 stock options with an exercise price of $4.10, as disclosed in a recent SEC Form 4 filing.

Terns Pharmaceuticals, Inc. Director Jill M. Quigley was granted 45,000 stock options with an exercise price of $4.10, aligning her incentives with long-term shareholder value.

Terns Pharmaceuticals, Inc. Director David A. Fellows was granted 45,000 stock options with an exercise price of $4.10, as reported in a recent SEC Form 4 filing.

Emil Kuriakose, Chief Medical Officer of Terns Pharmaceuticals, sold 952 shares of common stock on April 1, 2025, to cover taxes related to a restricted stock unit vesting.

Andrew Gengos, CFO of Terns Pharmaceuticals, reports the acquisition of 750,000 stock options with a vesting schedule commencing on February 24, 2025.

Director Robert Azelby reports acquisition of 90,000 stock options in Terns Pharmaceuticals, vesting over three years.

Director Hongbo Lu of Terns Pharmaceuticals acquired 10,657 stock options in lieu of a $40,000 cash retainer for 2025.

Radhika Tripuraneni, a director at Terns Pharmaceuticals, acquired stock options in lieu of a $40,000 cash retainer.

Director Jill M. Quigley of Terns Pharmaceuticals acquired stock options in lieu of a $40,000 cash retainer for 2025.

Terns Pharmaceuticals director Jeffrey B Kindler acquired 10,657 stock options in lieu of a $40,000 cash retainer.

David A. Fellows, a director at Terns Pharmaceuticals, received stock options in lieu of a $70,000 cash retainer for 2025.

Melita Sun Jung, Chief Business Officer of Terns Pharmaceuticals, acquired 2,250 shares and 325,000 stock options.

Terns Pharmaceuticals' Chief Medical Officer, Emil Kuriakose, was granted stock options for 485,000 shares on January 30, 2025.

Amy L. Burroughs, CEO of Terns Pharmaceuticals, reports the acquisition of common stock and stock options.

Terns Pharmaceuticals' Chief Medical Officer, Emil Kuriakose, sold 4,481 shares of common stock to cover taxes related to a vesting restricted stock unit award.

Terns Pharmaceuticals' Chief Financial Officer, Mark J. Vignola, sold a total of 17,188 shares of common stock in two transactions to cover tax obligations and under a pre-arranged trading plan.

Terns Pharmaceuticals director Jill M. Quigley sold shares of common stock to cover tax obligations and under a pre-arranged trading plan.

Terns Pharmaceuticals' Chief Medical Officer, Emil Kuriakose, was granted stock options for 120,000 shares on December 12, 2024.

Terns Pharmaceuticals CEO Amy L. Burroughs acquired 15,450 shares of common stock on December 5, 2024, including shares from the company's Employee Stock Purchase Plan.

Heather D Turner, a director at Terns Pharmaceuticals, acquired 64,000 stock options on November 18, 2024.

Director Hongbo Lu reports the acquisition of Terns Pharmaceuticals (TERN) common stock through indirect ownership via NEXTBio Master Fund LP and NEXTBio Opportunity Adapt LLC.

Mark J. Vignola, CFO of Terns Pharmaceuticals, exercised stock options and sold 10,000 shares of common stock at $11.00 per share on September 10, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Jill M. Quigley exercised stock options and sold shares of Terns Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Director Jill M. Quigley of Terns Pharmaceuticals sold shares of common stock to cover taxes and under a pre-arranged Rule 10b5-1 trading plan.

Director Carl L. Gordon reports selling Terns Pharmaceuticals (TERN) shares held indirectly through OrbiMed affiliated entities on July 15th and 16th, 2024.

OrbiMed Advisors LLC and related entities report the sale of Terns Pharmaceuticals (TERN) common stock, while maintaining significant indirect ownership.

Director Jill M. Quigley of Terns Pharmaceuticals exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Radhika Tripuraneni, a director at Terns Pharmaceuticals, acquired stock options in lieu of cash retainer fees, according to a recent SEC Form 4 filing.